Resources

This article was originally published in Genetic Engineering & Biotechnology News under the title of The Antimicrobial Resistance Crisis Eradicating a Global Health Threat

Reversing the Rapid Rise of Antibiotic Resistance. Greg Mario joins David E. Williams to discuss the real and potentially imminent dangers of antibiotic-resistant infections and the new technologies being developed to combat this growing threat.

Antimicrobial resistance (AMR) is not a new phenomenon; it has been a persistent challenge since the discovery of antibiotics. TAXIS Pharmaceuticals is at the forefront of addressing antimicrobial resistance, developing innovative antimicrobial solutions.

Startup Revolution: Greg Mario of TAXIS Pharmaceuticals On How Their Emerging Startup is Changing the Game

On July 25, House Budget Committee bipartisan roundtable entitled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline.”

Antibiotic resistance – or antimicrobial resistance (AMR) – has been making headlines for decades. At TAXIS Pharmaceuticals, we have been working since 2009 on the development of compounds that combat antimicrobial resistance.

TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia. Originally published in NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/

FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. In this paper, we present the screening and evaluation of a benzamide class that is functionalized at the alkoxy fragment targeting Gram-negative bacteria.

Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.